A reader's guide to economic analysis in the GI literature

American Journal of Gastroenterology

Volumn 91, Issue 12, 1996, Pages 2461-2470

  Provenzale, D ^a,b   Lipscomb, J ^a  

^a DUKE UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON; VACCINE;

CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; ECONOMICS; HEALTH CARE POLICY; HEMOCHROMATOSIS; HUMAN; INFORMATION SYSTEM; LIFE EXPECTANCY; LIVER BIOPSY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

COST-BENEFIT ANALYSIS; ECONOMICS, MEDICAL; EVALUATION STUDIES; GASTROENTEROLOGY; HEMOCHROMATOSIS; HUMANS; MASS SCREENING;

EID: 0029902528     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Provenzale D, Lipscomb J. Cost-effectiveness: Definitions and use in the gastroenterology literature. Am J Gastroenterol 1996;91:1488-93.
2. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs. Oxford: Oxford University Press, 1987.
3. Udvarhelyi S, Colditz GA, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature. Ann Intern Med 1992;116: 238-44.
4. Balan V, Baldus W, Fairbanks V, et al. Screening for hemochromatosis: A cost-effectiveness study based on 12,258 patients. Gastroenterology 1994;107:453-9.
5. Adams PC, Gregor JC, Kertesz AE, et al. Screening blood donors for hereditary hemochromatosis: Decision analysis model based on a 30-year database. Gastroenterology 1995;109:177-88.
6. Transition System I: Clinical Cost Manager. Boston: Transition Systems Inc.
7. St. Anthony's DRG Working Guidebook. Reston, Virginia: St. Anthony Publishing, Inc., 1996.
8. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-54.
9. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel J, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
10. Eisenstaedt RS, Getzen TE. Screening blood donors for immunodeficiency virus antibody: Cost-benefit analysis. Am J Public Health 1988;78:450-4.
11. Weinstein MC, Stason WB. Hypertension: A policy perspective. Cambridge, MA: Harvard University Press, 1976.
12. Weinstein MC, Fineberg HV. Clinical decisions and limited resources. In: Clinical decision analysis. Philadelphia: WB Saunders Company, 1980: 258, Table 8.7.
13. Eisenberg JM. Clinical economics: A guide to the economic analysis of clinical practices. JAMA, 1989;262:2879-86.
14. Finkler SA. The distinction between cost and charges. Ann Int Med 1982;96:102-9.
15. U.S. Congress, Office of Technology Assessment. Identifying health technologies that work: Searching for evidence, OTA-H-608. Washington, DC: U.S. Government Printing Office, September, 1994:241.